Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
On December 4, 2014, Telogis, Inc. (“Telogis”) agreed to waive service of the summons and complaint in the above captioned matter. (D.I. 6.) As a result, Telogis’response deadline is now February 2, 2015.
So at most a month until the next update.
Rothschild has 12 active litigations against pretty much anyone who uses GPS or location based services in their products. I don't see how their complaint can even stand in court because of how many people use this idea. It's like patenting the idea of a car and then suing everyone who makes one.
https://search.rpxcorp.com/lit/dedce-56044-rothschild-location-technologies-v-telogis
Email response
As a privately held company, Telogis is unable to share information about its investment plans or a projected timeline for an initial public offering.
Best,
-krys grondorf
Krys Card Grondorf
Vice President, Global Corporate communications - Telogis inc.
One Platform for Connected Intelligence
Someone break the .20s!!!
Just got a call from a girl at Telogis. I inquired about fleet services and when she called I asked about their going public, she said that she doesn't know, "that haven't released that to our pay grade" she said. She will email me the number for IR, so I might get something from them.
When T acquired our assets, were the obligated, or was rmtd, to release any info? I'm looking for something that says T owns the assets, I went through all of rmtds filings and saw no mention of T.
If T already has a private ticker symbol, what's to keep them from using that and going the regular ipo route instead of RM with RMTD?
Good volume, next leg up!
Don't know what I expected, 200 Chisholm place has new tenants and no sign or remnants of RD.
Just realized I live super close to RDs old office in plano and its on my way to work. I'm going to stop by there tomorrow morning just for kicks. Probably will be dark and desolate, but ya never know.
Translated for you all
( Business Wire ) Cytori Therapeutics (NASDAQ: CYTX) is , today , the United States Food and Drug Administration (FDA) is , conditions for the extremely important clinical trial named STAR, to exemption of investigational medical devices (IDE) announced that the attached approval was conducted . The purpose of the trial , as a potential treatment for dysfunctions of the hand with scleroderma , is to evaluate the Cytori Cell Therapy ™. Scleroderma is a rare autoimmune disease , there are about 50,000 patients in the United States .
Article of STAR approval , randomized , double-blind , is a placebo - control , it becomes extremely important trials that target 80 patients at up to 12 locations in the United States . This trial , a patient of there is a disease in hand finger scleroderma , and conducted a Cytori Cell Therapy alone , to evaluate its safety and efficacy . In the hands of 90% of patients , typical progressive disease that can cause chronic pain , the blood flow changes and serious dysfunction is out . Possible treatments are limited , but also can result in some diseases relaxation , changing the progress of the disease , it is impossible or substantially improve disease .
Cell therapy of Cytori of processing technology called Celution® System , which is classified as a medical device by the FDA of class III, prior to commercially available in the United States , and extremely important clinical trial success , premarket approval (PMA) is are required . Celution System is , to produce cell products for self- porting from adipose tissue-derived regeneration ( stem ) cells (ADRCs ™). STAR is predicated on the pilot trial SCLERADEC-I that was completed .
According to data published year , patients SCLERADEC-I , in four important and effective evaluation items to evaluate the systemic scleroderma patients clinical condition with dysfunction hand , average , 6 I showed a 50% improvement in disease month . This data has been published in the Annals of the Rheumatic Diseases of May 2014 .
In STAR, it is planned to use the Cochin Hand Function Scale score is a valid measure of the hands of the function , as primary endpoint to be measured after June of a single implementation of Cytori Cell Therapy or placebo . Patients in the placebo group , after all patients had completed follow-up of 12 months , can be subjected to cross -over to the arm was trial . For more information about the trial , will be announced after reaching the final agreement with the FDA. The trial is expected to recruit in 2015 is started .
President and CEO of Cytori, Dr. Marc Hedrick said, " STAR is , and be established advanced and innovative treatment , the most promising ones to focus on that which is introduced into the facility , direct of our new strategy such is the result . We , in this trial , data that matches the effectiveness of sign that has been confirmed in clinical trials that have been published recently and I hope to be seen . in addition , the nature of the hand of failure due to scleroderma is rare , it is said that through a very important clinical trial , it is possible to fully commercialize . " .
Through team of Cytori is , within a period of JP Morgan Healthcare Conference to be held on January 12 to 15 in San Francisco, is scheduled to be held the information exchange meeting that incorporates a Q & A about the STAR. Details will be announced at the press release in December and chasing . For scleroderma Scleroderma , by generating excessive systemic collagen , skin Senka , is a chronic autoimmune disease with lesions of blood vessels and various organs .
Scleroderma , women who are four times more developed than men , with a predilection for the 30-year-old to 50 -year-old . In most cases , appear diseases hand . In the estimation of the National Institute of Arthritis and Musculoskeletal and Skin Diseases ( arthritis and musculoskeletal / skin disease National Research Organization ) , patients with systemic scleroderma in the United States about 50,000 people . As a method of treatment , in addition to protect the hands from injury and adverse environment, also be used vasodilators . The disease progresses , there is a case where immunosuppressive agent is used , it is often accompanied by side effects which can not be Junin .
Cytori Therapeutics, Inc.
Tiago Girao
Chief Financial Officer - US
1-858-458-0900
ir@cytori.com
or
Seijiro Shirahama
President - Asia Pacific
Phone +81.3.5319.8371
sshirahama@cytori.com
Entry prices everyone? I'm in at .09
Just games. Throw signals to keep the interest up. They probably find it hilarious that anyone is actually on this board. Though the volume over the past year has been worth noting after such a long silent period.
You're in this too? Nice! I think this will be a real winner other than W. Go GTRQ!!
Along with the other lurkers on this board, I believe we will get our payday in due time. Board activity and volume alone speak for itself. Along with the other pieces to this puzzle I think this could be a nice gift within a year. No money lost where we sit and I'm willing to hold as long as it takes. Play with money you can afford to lose.
Nice to see trading picking up. Looks good.
Gary Hallgren is still listed as the CEO of RMTD on OTCMarkets.com, which probably hasn't been updated in ages. He is now the Senior Vice President of Corporate Strategy at Telogis. RemoteDynamics.com has also been routed to Telogis.com as well. We know that Telogis bought Remote Dynamics in 2010, so there is plenty of connections here to assume a good relation.
Telogis raised 93M in 2013 but decided to spend that money on "R&D," which I think is the key phrase here. Anything could be considered "R&D," even preparing for a Reverse Merger. The company that gave them the money is called Kleiner Perkins Caufield & Byers, who specializes in bringing companies public. That's what they do. I don't think they would fork over that much money to a private company without seeing some return on their investment.
The SEC requires the shell company to file an 8K document to announce the action of a Reverse Merger. That's what we're looking for, or an S-1 but that would likely come after the 8K if at all.
On KPCB's website, they have a list of all of their recent ventures and companies that they have taken public. They also have teams of people that handle multiple companies and their IPOs. Telogis is listed on the Greentech team and its members are: Amol Deshpande, John Doerr, Al Gore (THAT Al Gore), Wen Hsieh, Rob Johnson, Jan van Dokkum, Paul Yeh, Zach Barasz, Ben Kortlang, Maritza Liaw, Michael Linse, David Mount, Daniel Oros, Ryan Popple, and Brook Porter.
Link to that page: http://www.kpcb.com/teams/greentech
You can click on their image and get an email address for them. These are the people that know what is going on with Telogis, these are the people we need to talk to. I've sent a couple emails and I suggest any investor in RMTD do the same.
MODs: Can you guys sticky this and post #27657 please.
Awe yea! Not about to give up when the good news has just started! Lol
Just lurking for some time now lol small position @ .09
interesting.. I called six flags corporate to find out more, but alas its past 5pm and had to leave a voice mail. If I don't get a call back tomorrow then I'll try again on monday after the long holiday weekend.
I think they're using it as a tax benefit. When I called the CEO he said that funding was already in place and it's just a matter of time when the bigger players want in.
Would make for one hell of a 4th of July weekend!
Well today is looking good, hope this is the start of a trend..
Yea didn't think we'd be seeing a bounce with new hod all day, that's for sure. The past few days though have presented a great opportunity for buying though.
Kinda like what warren buffet said "buy when people are fearful and sell when people are greedy" something like that. Which boils down to "buy the dips, sell the rips" lol
In what way would that be?
Templetons touch??
I have called a couple times, I heard the story. Only time will tell if any of it is true... Holding my breath lol
Some dead cats bounce really well apparently..
Next real level of support is in the .0075 area :( I really hope this IS the bottom.
Very good post! I agree completely. If people did the opposite of small bid whacking and instead did small ask slapping I think we could gain some momentum here.
People need to call the CEO and find out for their own what exactly is going on here.
Well at least SA is on our side, I guess that's something. We could really use one of those billionaires to pony up right about now...
Nice 24% today, S1 before too long.
The party is all here! QASP ready to fly!
Nice! Keep going! IACH!!
Well at least that's some good news man, hope you're doing alright. I'm with ya.. IACH!!
Who can I contact at the SEC about this?
Has anyone called?
This is just a really bad case of "sell the news." I think when people realize that IACH is worth more than .015 they'll stop this massacre.
We were promised news and they delivered.. wtf is up with this chit??